Show simple item record

dc.contributor.authorGonzález González, Aliciaes_ES
dc.contributor.authorMediavilla Aguado, María Dolores es_ES
dc.contributor.authorSánchez Barceló, Emilio José es_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2018-02-19T18:23:19Z
dc.date.available2018-02-19T18:23:19Z
dc.date.issued2018es_ES
dc.identifier.issn1420-3049es_ES
dc.identifier.issn1433-1373es_ES
dc.identifier.urihttp://hdl.handle.net/10902/13067
dc.description.abstractThe objective of this article is to review the basis supporting the usefulness of melatonin as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high risk for this disease. Melatonin, as a result of its antiestrogenic and antioxidant properties, as well as its ability to improve the efficacy and reduce the side effects of conventional antiestrogens, could safely be associated with the antiestrogenic drugs presently in use. In individuals at risk of BC due to night shift work, the light-induced inhibition of melatonin secretion, with the consequent loss of its antiestrogenic effects, would be countered by administering this neurohormone. BC risk from exposure to metalloestrogens, such as cadmium, could be treated with melatonin supplements to individuals at risk of BC due to exposure to this xenoestrogen. The BC risk related to obesity may be reduced by melatonin which decrease body fat mass, inhibits the enhanced aromatase expression in obese women, increases adiponectin secretion, counteracts the oncogenic effects of elevated concentrations of leptin; and decreases blood glucose levels and insulin resistance. Despite compelling experimental evidence of melatonin?s oncostatic actions being susceptible to lowering BC risk, there is still a paucity of clinical trials focused on this subject.es_ES
dc.format.extent21 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceMolecules 2018, 23(2): 336es_ES
dc.titleMelatonin: A Molecule for Reducing Breast Cancer Riskes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/molecules23020336es_ES
dc.type.versionpublishedVersiones_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 EspañaExcept where otherwise noted, this item's license is described as Atribución 3.0 España